GeoVax Labs, Inc. announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion.
http://www.freshnews.com/news/889743/geovax-announces-preliminary-top-line-results-phase-1-therapeutic-vaccine-trial-hiv-inf
http://www.freshnews.com/news/889743/geovax-announces-preliminary-top-line-results-phase-1-therapeutic-vaccine-trial-hiv-inf
No comments:
Post a Comment